Psychiatr Prax 2014; 41(01): 8-10
DOI: 10.1055/s-0033-1359957
Editorial
© Georg Thieme Verlag KG Stuttgart · New York

Psychotherapie bei schizophrenen Störungen: Kein Evidenz-, sondern ein Implementierungsproblem

Psychotherapy of Schizophrenia: Not a Problem of Evidence, but a Problem of Implementation
Andreas Bechdolf
1   Kliniken für Psychiatrie, Psychotherapie und Psychosomatik, Vivantes Klinikum am Urban und Vivantes Klinikum im Friedrichshain, Akademische Lehrkrankenhäuser Charité – Universitätsmedizin Berlin
2   Klinik für Psychiatrie und Psychotherapie, Klinikum der Universität zu Köln
3   ORYGEN Youth Health, University of Melbourne, Melbourne, Australia
,
Stefan Klingberg
4   Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum Tübingen
› Author Affiliations
Further Information

Publication History

Publication Date:
14 January 2014 (online)

Schizophrene Störungen gehören zu den fünf Erkrankungen, bei denen die meisten Lebensjahre in Behinderung verbracht werden [1]. Die Erkrankung geht mit großem subjektivem Leid der Betroffenen und Angehörigen einher. 5 % der Betroffenen versterben an einem Suizid [2].

 
  • Literatur

  • 1 Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-1442
  • 2 Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol 2010; 24 (Suppl. 04) 81-90
  • 3 Mueser KT, Salyers MP, Mueser PR. A prospective analysis of work in schizophrenia. Schizophr Bull 2001; 27: 281-296
  • 4 Lieberman JA, Stroup TS, McEvoy JP et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223
  • 5 Keefe R. Cognitive deficits in patients with schizophrenia: effects and treatment. J Clin Psychiatry 2006; 68: 8-13
  • 6 Robinson D, Woerner MG, Alvir JM et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiat 1999; 56: 241-247
  • 7 Rüsch N, Berger M, Finzen A, Angermeyer M. Das Stigma psychischer Erkrankungen – Ursachen, Formen und therapeutische Konsequenzen. In: Berger M, Hrsg. Psychische Erkrankungen: Klinik und Therapie. 3.. Auflage. München: Urban & Fischer; 2009: 1091-1100
  • 8 Bäuml J, Froböse T, Kraemer S et al. Psychoeducation: a basic psychotherapeutic intervention for patients with schizophrenia and their families. Schizophr Bull 2006; 32 (Suppl. 01) S1-S9
  • 9 Bechdolf A, Knost B, Kuntermann C et al. A randomized comparison of group cognitive‐behavioural therapy and group psychoeducation in patients with schizophrenia. Acta Psychiatr Scand 2004; 110: 21-28
  • 10 Bechdolf A, Köhn D, Knost B et al. A randomized comparison of group cognitive‐behavioural therapy and group psychoeducation in acute patients with schizophrenia: outcome at 24 months. Acta Psychiatr Scand 2005; 112: 173-179
  • 11 Buchkremer G, Klingberg S, Holle R et al. Psychoeducational psychotherapy for schizophrenic patients and their key relatives or care-givers: results of a 2‐year follow‐up. Acta Psychiatr Scand 1997; 96: 483-491
  • 12 Klingberg S, Wittorf A, Meisner C et al. Cognitive behavioural therapy versus supportive therapy for persistent positive symptoms in psychotic disorders: The POSITIVE Study, a multicenter, prospective, single-blind, randomised controlled clinical trial. Trials 2010; 11: 123
  • 13 Wykes T, Steel C, Everitt B et al. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull 2008; 34: 523-537
  • 14 Driessen E, Hollon SD. Cognitive behavioral therapy for mood disorders: efficacy, moderators and mediators. Psychiatr Clin North Am 2010; 33: 537-555
  • 15 Pharoah F, Mari J, Rathbone J et al. Family intervention for schizophrenia. Cochrane Database Syst Rev 2010; (12) CD000088
  • 16 Psaty BM, Lumley T, Furberg CD et al. Health outcomes associated with various antihypertensive therapies used as first-line agents. JAMA 2003; 289: 2534-2544
  • 17 McGurk SR, Twamley EW, Sitzer DI et al. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry 2007; 164: 1791-1802
  • 18 Xia J, Merinder LB, Belgamwar MR. Psychoeducation for schizophrenia. Cochrane Database Syst Rev 2011; (06) CD002831
  • 19 van der Gaag M, Smit F, Bechdolf A et al. Preventing a first episode of psychosis: Meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res 2013; 149: 56-62
  • 20 National Institute for Health and Clinical Excellence Schizophrenia. NICE clinical guideline 82. Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). Im Internet: http://publications.nice.org.uk/schizophrenia-cg82 (Stand: 27.11.2013)
  • 21 Dixon LB, Dickerson F, Bellack AS et al. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull 2010; 36: 48-70
  • 22 Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN). S3 Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1 – Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff-Verlag; 2005
  • 23 Görgen W, Engler U. Ambulante psychotherapeutische Versorgung von psychosekranken Menschen sowie älteren Menschen in Berlin. Heidelberg: Verlagsgruppe Hüthig Jehle Rehm; 2005
  • 24 Wittmann WW, Lutz W, Steffanowski A et al. Qualitätsmonitoring in der ambulanten Psychotherapie: Modellprojekt der Techniker Krankenkasse – Abschlussbericht. Hamburg: Techniker Krankenkasse; 2011
  • 25 Rummel-Kluge C, Pitschel-Walz G, Bäuml J et al. Psychoeducation in schizophrenia – results of a survey of all psychiatric institutions in Germany, Austria, and Switzerland. Schizophr Bull 2006; 32: 765-775
  • 26 Kemp R, Hayward P, Applewhaite G et al. Compliance therapy in psychotic patients: randomised controlled trial. BMJ 1996; 312: 345-349
  • 27 Kemp R, Kirov G, Everitt B et al. Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry 1998; 172: 413-419